Solid Tumor, AdultPhase 1NCT03496519
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
A Phase 1 study testing Dose Escalation of Durvalumab and Trabectedin and Dose Expansion of Durvalumab and Trabectedin in people with Solid Tumor, Adult, run by University of Colorado, Denver.
Trial summary
A phase 1 study examining the combination of Durvalumab (MEDI4736) and Trabectedin in various solid tumor types. The study seeks to determine a safe dose of the combination of study drugs and then examine this dose in larger groups of patients of specific tumor types to evaluate its anti-tumor efficacy. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Solid Tumor, Adult
- What is being tested?
- Dose Escalation of Durvalumab and Trabectedin and Dose Expansion of Durvalumab and Trabectedin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2018to 31 Oct 2021
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ability to understand and the willingness to sign a written informed consent document
- Written informed consent and any locally-required authorization (e.g., HIPAA in the USA) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations
- AGE ≥ 18
- Alkaline phosphatase (ALP) level ≤ upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine amino transferase (ALT) ≤ ULN
- Bilirubin ≤ ULN, if total bilirubin is > ULN, measure direct/indirect bilirubin to evaluate for Gilbert's Syndrome (if direct bilirubin is within normal range, subject may be eligible)
Show all 27Show fewer
- Albumin ≥ 2.5 g/dL
- CPK ≤ 2.5 xULN
- Body weight > 30 kg
- ECOG performance status 0-1
- Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- Evaluable disease for dose escalation, measurable disease per RECIST 1.1 for dose expansions
- Hemoglobin ≥ 9 g/dL
- Neutrophil count ≥ 1.5 x 10^9/L
- Platelets ≥ 100 x 10^9/L
- Measured creatinine clearance (CL) ≥ 50 mL/min or Calculated creatinine CL≥ 50 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:
- This calculation will be performed by a member of the clinical study team
- Males:
- Creatinine CL (mL/min) = Weight (kg) x (140 - Age) / 72 x serum creatinine (mg/dL)
- Females:
- Creatinine CL (mL/min) = [Weight (kg) x (140 - Age)/72 x serum creatinine (mg/dL)] x 0.85
- Any advanced unresectable/stage IV solid tumor with exception of primary CNS malignancy is permitted.
- Enrolled patients may be candidates for standard of care therapy with trabectedin or second line/subsequent line treatment for advanced disease with PD-1/PD-L1 inhibitor monotherapy. Otherwise they should have no standard of care option available or be felt appropriate for a phase I clinical trial in the opinion of the treating investigator. Prior PD-1/PD-L1 exposure is not an exclusion criteria.
- For the expansion cohort of NSCLC patients previously treated with and having progressed on immunotherapy patients must have no standard of care option available or have contraindications to such treatment (including those who decline such treatment).
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and exams including follow up.
Who cannot join
- Strong inhibitors or inducers of cytochrome P450 3A (washout from prior use of such agents before C1D1 must exceed 21 days).
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
- Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies or other investigational product) ≤ 28 days. However, if a therapy has a short half-life, then patients may participate if they received prior treatment ≤ 28 days before starting study treatment with approval from the PI and AstraZeneca/Janssen. Acceptable washout periods include:
- 3-14 days for prior TKI depending on half-life
- 14-28 days for prior PD-1 or PD-L1 inhibitor treatment depending on the frequency of administration (i.e., wait one full cycle of prior PD-1 axis inhibition before starting study drugs)
- Therapeutic radiation within 6 weeks of cycle 1 day 1. Exceptions are palliative radiation and/or stereotactic radiation to non-target lesions.
Show all 42Show fewer
- If received prior immunotherapy must not have experienced one of the following:
- A toxicity that led to permanent discontinuation of prior immunotherapy
- All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study.
- Must not have experienced a ≥Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE: Patients with endocrine AE of ≤Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.
- Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE and must not have experienced recurrence of an AE if re-challenged.
- Prior treatment with trabectedin or trabectedin analog
- History of another malignancy except for:
- Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study drugs and of low potential risk for recurrence
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
- Mean QT interval corrected for heart rate (QTc) > 450 ms for males or > 470 msec for females calculated from 3 electrocardiograms (ECGs) using Fredericia's Formula (within at least 15 minutes, at least 5 minutes apart)
- Current or prior use of systemic immunosuppressive medication within 28 days before the first dose of durvalumab + trabectedin, with the exception of systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. The following are exceptions to this criterion:
- Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
- Any unresolved toxicity (non-immune mediated) NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia
- However, patients with irreversible toxicity not reasonably expected to be exacerbated by the treatment with durvalumab + trabectedin may be included only after consultation with the Principal Investigator.
- Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study drugs. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- History of allogenic organ transplantation (both solid organ and bone marrow)
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- Patients with vitiligo or alopecia
- Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
- Any chronic skin condition that does not require systemic therapy
- Patients without active disease in the last 5 years may be included, but only after consultation with the PI
- Patients with celiac disease controlled by diet alone
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- Cirrhosis of any Child Pugh class
- Left ventricular ejection fraction less than 50%
- History of pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis or evidence of symptomatic interstitial lung disease on chest computed tomography (CT).
- History of leptomeningeal carcinomatosis
- Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis that meets RECIST criteria identified either on the baseline brain imaging obtained during the screening period or identified prior to signing the informed consent form (ICF). Patients whose brain metastases have been treated may participate provided they show radiographic stability (defined as 2 brain images, both of which are obtained after treatment to the brain metastases. These imaging scans should both be obtained at least four weeks apart and show no evidence of intracranial progression). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable either, without the use of steroids, or are stable on a steroid dose of ≤10mg/day of prednisone or its equivalent and not requiring anticonvulsants for at least 14 days prior to the start of treatment.
- History of active primary immunodeficiency
- Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (HBsAg positive), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HbsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of study drugs. Note: Patients, if enrolled, should not receive live vaccine whilst receiving treatment with study drugs and up to 90 days after the last dose of study drugs.
- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control (as defined in section 7.1 of protocol) from screening to 180 days after receipt of the last dose of study drugs.
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
- Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.
About this study
Official title: A Phase I Study Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
A phase 1 study examining the combination of Durvalumab (MEDI4736) and Trabectedin in various solid tumor types. The study seeks to determine a safe dose of the combination of study drugs and then examine this dose in larger groups of patients of specific tumor types to evaluate its anti-tumor efficacy. Treatment will continue in patients who respond for up to 1 year.
Read the detailed description
This study will include dose escalation and dose expansion phases.
In the dose escalation portion, patients with advanced cancer will be enrolled and treated with Durvalumab and Trabectedin. Durvalumab will be administered at the same dose in each dose escalation cohort, while the dose of Trabectedin will be progressively increased in different cohorts until the safest dose of the combination is determined.
In the dose expansion portion patients will be treated with the safest dose of the study drugs determined during the dose escalation phase. There will be two separate groups of patients treated at this dose to evaluate anti-tumor efficacy of the combination. One group will consist of non-small-cell lung cancer patients previously treated with PD-1 or PD-L1 inhibitors and another group will consist of an immunotherapy naive group of patients. This immunotherapy naive group of patients will include sarcoma and another tumor type, this other tumor type will be determined based on anti-tumor efficacy seen during the dose escalation.
The study drugs will be given intravenously every 3 weeks. Treatment will continue for up to one year or until disease progression.
- Conditions
- Solid Tumor, Adult
- Being tested
- Dose Escalation of Durvalumab and Trabectedin, Dose Expansion of Durvalumab and Trabectedin
- Keywords
- Durvalumab, Trabectedin, Maximum Tolerated Dose, Lung Cancer, Sarcoma
- Medical subject headings
- Lung Neoplasms, Sarcoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dose Escalation of Durvalumab and TrabectedinDrug
Also called Combination of Durvalumab and Trabectedin
There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
- Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2
- Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2
- Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2
- Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2
- Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2
Dose Expansion of Durvalumab and TrabectedinDrug
Also called Combination of Durvalumab and Trabectedin
There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
| Study group | Role | What they receive |
|---|---|---|
| Dose Escalation | Experimental | Dose escalation will occur following a 3+3 design in all advanced tumor types meeting the inclusion and exclusion criteria.
* Cohort -1 (if necessary): Durvalumab 1125mg with Trabectedin 0.5mg/m2
* Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2
* Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2
* Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2
* Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2 Receives: Drug: Dose Escalation of Durvalumab and Trabectedin |
| Dose Expansion | Experimental | Patients at this level will receive the safest dose of Durvalumab and Trabectedin that was determined during the Dose Escalation Phase. There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be fixed dosage of Trabectedin for each cohort, given through intravenous infusion as an outpatient, over a 24 hour period on Day 1 every 21 days. Receives: Drug: Dose Expansion of Durvalumab and Trabectedin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recommended Dosage of the Durvalumab and Trabectedin Combination
Recommended Phase II Dose (RP2D) is the dose determined safest for further evaluation based on both early and late onset side effects detected during the dose escalation phase.
Measured: Up to 1 year on study treatment plus 90 days safety follow-up, up to 15 months
Maximum tolerated dose
Maximum Tolerated Dose (MTD) is defined as the highest dose level with no more than 1 Dose Limiting Toxicity (DLT) reported out of up to 6 DLT-evaluable subjects determined during the dose escalation phase
Measured: First 2 cycles at 21 days each, equal to 42 days.
Secondary outcomes (7)
Overall Response Rate (ORR) of the Durvalumab and Trabectedin Combination in the whole treated population and at the RP2D in the expansion cohort(s)
ORR is determined by RECIST v1.1 and iRECIST response criteria.
Measured: After 2 cycles of study drugs to study end date, up to 24 months.
Duration of Response (DOR) of the Durvalumab and Trabectedin Combination
The time period for which a partial response (PR) or complete response (CR) is maintained.
Measured: After 2 cycles of study drugs, up to 24 months.
Clinical Benefit Rate (CBR) of the Durvalumab and Trabectedin Combination
Determined by complete response, partial response, or stable disease.
Measured: After 2 cycles of study drugs to study end date, up to 24 months.
One Year Progression Free Survival (PFS) of the Durvalumab and Trabectedin Combination
PFS is determined by RECIST v1.1 and iRECIST
Measured: Study start date to progression, or death, whichever comes first, up to 24 months.
One Year Overall Survival (OS) of the Durvalumab and Trabectedin Combination
Determined continuously throughout the study.
Measured: Study start date to death from any cause, up to 24 months.
Incidence of Treatment-Emergent Adverse Events (Safety)
Number of participants with abnormal laboratory values and/or adverse events that are related to treatment.
Measured: Study start date to study end date, up to 24 months.
Incidence of Treatment-Emergent Adverse Events (Tolerability)
Number of participants with abnormal laboratory values and/or adverse events that are related to treatment.
Measured: Study start date to study end date, up to 24 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Apr 2018
- Study start1 Oct 2018 (estimated)
- Primary completion31 Oct 2021 (estimated)
- Study completion31 Oct 2021 (estimated)
Why it stopped: Contract Issues
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid Tumor, AdultStudies of the same condition, open and under way.
- More trials run by University of Colorado, DenverThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Colorado, Denver
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jose Pacheco, Principal investigator, University of Colorado, Denver
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03496519
- Sponsor's protocol ID
- 17-1852.cc
- Status last verified
- Oct 2018
- First submitted
- 23 Mar 2018
- Last updated
- 9 Oct 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Study Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
- ClinicalTrials.gov ID
- NCT03496519
- Acronym / sponsor ID
- 17-1852.cc
- Conditions
- Solid Tumor, Adult
- Keywords
- Durvalumab, Trabectedin, Maximum Tolerated Dose, Lung Cancer, Sarcoma
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Contract Issues
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of Colorado, DenverUniversity, hospital or other
- Study start
- 1 Oct 2018 (estimated)
- Primary completion
- 31 Oct 2021 (estimated)
- Study completion
- 31 Oct 2021 (estimated)
- First posted
- 12 Apr 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A phase 1 study examining the combination of Durvalumab (MEDI4736) and Trabectedin in various solid tumor types. The study seeks to determine a safe dose of the combination of study drugs and then examine this dose in larger groups of patients of specific tumor types to evaluate its anti-tumor efficacy. Treatment will continue in patients who respond for up to 1 year.
Detailed description
This study will include dose escalation and dose expansion phases.
In the dose escalation portion, patients with advanced cancer will be enrolled and treated with Durvalumab and Trabectedin. Durvalumab will be administered at the same dose in each dose escalation cohort, while the dose of Trabectedin will be progressively increased in different cohorts until the safest dose of the combination is determined.
In the dose expansion portion patients will be treated with the safest dose of the study drugs determined during the dose escalation phase. There will be two separate groups of patients treated at this dose to evaluate anti-tumor efficacy of the combination. One group will consist of non-small-cell lung cancer patients previously treated with PD-1 or PD-L1 inhibitors and another group will consist of an immunotherapy naive group of patients. This immunotherapy naive group of patients will include sarcoma and another tumor type, this other tumor type will be determined based on anti-tumor efficacy seen during the dose escalation.
The study drugs will be given intravenously every 3 weeks. Treatment will continue for up to one year or until disease progression.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dose Escalation | Experimental | Drug: Dose Escalation of Durvalumab and TrabectedinDose escalation will occur following a 3+3 design in all advanced tumor types meeting the inclusion and exclusion criteria. * Cohort -1 (if necessary): Durvalumab 1125mg with Trabectedin 0.5mg/m2 * Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2 * Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2 * Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2 * Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2 |
| Dose Expansion | Experimental | Drug: Dose Expansion of Durvalumab and TrabectedinPatients at this level will receive the safest dose of Durvalumab and Trabectedin that was determined during the Dose Escalation Phase. There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be fixed dosage of Trabectedin for each cohort, given through intravenous infusion as an outpatient, over a 24 hour period on Day 1 every 21 days. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (27 listed)
- Ability to understand and the willingness to sign a written informed consent document
- Written informed consent and any locally-required authorization (e.g., HIPAA in the USA) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations
- AGE ≥ 18
- Alkaline phosphatase (ALP) level ≤ upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine amino transferase (ALT) ≤ ULN
Key exclusion criteria (42 listed)
- Strong inhibitors or inducers of cytochrome P450 3A (washout from prior use of such agents before C1D1 must exceed 21 days).
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
- Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies or other investigational product) ≤ 28 days. However, if a therapy has a short half-life, then patients may participate if they received prior treatment ≤ 28 days before starting study treatment with approval from the PI and AstraZeneca/Janssen. Acceptable washout periods include:
- Therapeutic radiation within 6 weeks of cycle 1 day 1. Exceptions are palliative radiation and/or stereotactic radiation to non-target lesions.
- If received prior immunotherapy must not have experienced one of the following:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dose Escalation of Durvalumab and TrabectedinAlso: Combination of Durvalumab and TrabectedinThere will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient. * Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2 * Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2 * Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2 * Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2 * Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2 | Drug | Dose Escalation |
| Dose Expansion of Durvalumab and TrabectedinAlso: Combination of Durvalumab and TrabectedinThere will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient. | Drug | Dose Expansion |
Primary outcome
Recommended Dosage of the Durvalumab and Trabectedin Combination
Time frame: Up to 1 year on study treatment plus 90 days safety follow-up, up to 15 months
Recommended Phase II Dose (RP2D) is the dose determined safest for further evaluation based on both early and late onset side effects detected during the dose escalation phase.
Maximum tolerated dose
Time frame: First 2 cycles at 21 days each, equal to 42 days.
Maximum Tolerated Dose (MTD) is defined as the highest dose level with no more than 1 Dose Limiting Toxicity (DLT) reported out of up to 6 DLT-evaluable subjects determined during the dose escalation phase
7 secondary outcomes
Overall Response Rate (ORR) of the Durvalumab and Trabectedin Combination in the whole treated population and at the RP2D in the expansion cohort(s)
Time frame: After 2 cycles of study drugs to study end date, up to 24 months.
Duration of Response (DOR) of the Durvalumab and Trabectedin Combination
Time frame: After 2 cycles of study drugs, up to 24 months.
Clinical Benefit Rate (CBR) of the Durvalumab and Trabectedin Combination
Time frame: After 2 cycles of study drugs to study end date, up to 24 months.
One Year Progression Free Survival (PFS) of the Durvalumab and Trabectedin Combination
Time frame: Study start date to progression, or death, whichever comes first, up to 24 months.
One Year Overall Survival (OS) of the Durvalumab and Trabectedin Combination
Time frame: Study start date to death from any cause, up to 24 months.
Incidence of Treatment-Emergent Adverse Events (Safety)
Time frame: Study start date to study end date, up to 24 months.
Incidence of Treatment-Emergent Adverse Events (Tolerability)
Time frame: Study start date to study end date, up to 24 months.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2018.
Related trials for Solid Tumor, Adult
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
Active, not recruitingPhase 1
Advanced or Recurrent Solid Tumors Treated With SHetA2
Solid Tumor, Adult
RecruitingObservational study
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Very Rare Tumors, Very Rare Cancers
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
RecruitingPhase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Solid Tumor, Advanced Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jose Pacheco principal investigator
University of Colorado, Denver
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Dose Escalation of Durvalumab and Trabectedin and Dose Expansion of Durvalumab and Trabectedin in people with Solid Tumor, Adult, run by University of Colorado, Denver.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 27 inclusion and 42 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 9 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recommended Dosage of the Durvalumab and Trabectedin Combination (time frame: Up to 1 year on study treatment plus 90 days safety follow-up, up to 15 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2018.